You are here
CRT has an unusually broad portfolio of cancer-focused projects, a pipeline that rivals most pharmas', and we're ranked second for the number of oncology licenses completed.
CRT currently has more than 30 partnered agents in pre-clinical and clinical development, two drugs in phase III trials and four drugs already on the market and benefiting patients.
CRT has more than 200 oncology-focused projects under development and potentially available for licensing or collaboration. The projects range from discovery to clinical.